Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: AbbVie (ABBV), Molina Healthcare (MOH) and Ocular Therapeutix (OCUL)

Tipranks - Tipranks - Wed Apr 1, 1:04PM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on AbbVie (ABBV), Molina Healthcare (MOH) and Ocular Therapeutix (OCUL).

End of Quarter Sale - 50% Off TipRanks

AbbVie (ABBV)

In a report released yesterday, Courtney Breen from Bernstein maintained a Hold rating on AbbVie, with a price target of $225.00. The company’s shares closed last Tuesday at $216.94, close to its 52-week high of $218.66.

According to TipRanks.com, Breen is a 4-star analyst with an average return of 19.4% and a 84.1% success rate. Breen covers the Healthcare sector, focusing on stocks such as Bristol-Myers Squibb, Gilead Sciences, and Merck & Company. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for AbbVie with a $253.47 average price target, which is a 17.9% upside from current levels. In a report issued on March 21, TipRanks – xAI also reiterated a Hold rating on the stock with a $216.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Molina Healthcare (MOH)

Bernstein analyst Lance Wilkes maintained a Buy rating on Molina Healthcare yesterday and set a price target of $173.00. The company’s shares closed last Tuesday at $133.62.

According to TipRanks.com, Wilkes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -8.7% and a 32.7% success rate. Wilkes covers the Healthcare sector, focusing on stocks such as Elevance Health, HCA Healthcare, and Agilon Health. ;'>

Currently, the analyst consensus on Molina Healthcare is a Hold with an average price target of $143.00.

Ocular Therapeutix (OCUL)

Piper Sandler analyst Biren Amin maintained a Buy rating on Ocular Therapeutix yesterday and set a price target of $31.00. The company’s shares closed last Tuesday at $8.31.

According to TipRanks.com, Amin is a 4-star analyst with an average return of 7.8% and a 45.9% success rate. Amin covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, OKYO Pharma Limited Sponsored ADR, and BridgeBio Oncology Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Ocular Therapeutix with a $25.38 average price target, representing a 237.1% upside. In a report issued on March 27, H.C. Wainwright also reiterated a Buy rating on the stock with a $21.00 price target.

Read More on ABBV:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).